Kailera Therapeutics, Inc Common Stock

Kailera Therapeutics, Inc Common Stock

Yahoo Finance • last month

Kailera Therapeutics (KLRA) is One of the Best IPO Stocks with Huge Upside Potential

Kailera Therapeutics Inc. (NASDAQ:KLRA) is one of the best IPO stocks with huge upside potential. On July 7, Kailera Therapeutics announced positive topline results from two Phase 3 clinical trials conducted by Hengrui Pharma for HRS-7535/... Full story

Yahoo Finance • last month

Obesity drug developer Kalohexis files confidentially for U.S. IPO

[IPO Initial Public Offering on Financial Stock Market Chart 3D render] gonin Kalohexis, a clinical-stage biotech developing a series of peptide therapies for conditions including obesity, announced on Tuesday that it has confidentially f... Full story

Yahoo Finance • last month

Eli Lilly's Market Cap Balloons Again On This IPO's Setback

Eli Lilly shares hit a record high Tuesday after IPO stock Kailera Therapeutics posted lackluster test results for its weight-loss pill. Continue Reading... Full story

Yahoo Finance • 2 months ago

Kardigan rises in Nasdaq debut after upsized $400 million IPO

June 18 (Reuters) - Kardigan's shares rose 1.6% in their Nasdaq debut on ‌Thursday, after the heart drug ‌developer raised $400 million in an upsized U.S. initial ​public offering. The Princeton, New Jersey-based company's shares opened a... Full story

Yahoo Finance • 2 months ago

Notable healthcare headlines for the week: GSK, Parabilis Medicines, and Novo Nordisk in focus

Wall Street traded higher on Friday as investors focused on the highly anticipated public debut of SpaceX, with enthusiasm surrounding the offering helping support gains across major U.S. equity indexes. The blue-chip Dow Jones Industrial... Full story

Yahoo Finance • 3 months ago

Is Kailera Therapeutics a Buy After Its Sizzling IPO?

In the biotech sector, private companies are moving from the sidelines into the spotlight through initial public offerings (IPOs). One of the most recent is Kailera Therapeutics(NASDAQ: KLRA), a potential competitor to Eli Lilly and Novo N... Full story

Yahoo Finance • 3 months ago

This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst

On Tuesday, William Blair initiated coverage on Kailera Therapeutics Inc.(NASDAQ:KLRA), the latest entrant in the fast-growing weight-loss drug market. The obesity-focused biotech raised more than $600 million in April through an initial... Full story

Yahoo Finance • 3 months ago

Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In Obesity

Analysts initiated covered Tuesday of IPO stock Kailera Therapeutics, a potential competitor to Lilly and Novo in obesity treatment. Continue Reading... Full story

Yahoo Finance • 3 months ago

Kailera IPO And Governance Overhaul Set Terms For NASDAQ Composite Debut

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Kailera Therapeutics (NasdaqGS:KLRA) completed its initial public... Full story

Yahoo Finance • 3 months ago

A Kailera Therapeutics (KLRA) Insider Scooped up an Additional 500,000 Shares for $8.0 Million

On April 20, 2026, RTW Investments, a 10% Owner of Kailera Therapeutics(NASDAQ:KLRA), reported the acquisition of 500,000 shares of common stock at $16.00 per share, according to the SEC Form 4 filing. The firm also received 10.28 million... Full story